Nebula Research & Development LLC Takes $639,000 Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Nebula Research & Development LLC bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,560 shares of the company's stock, valued at approximately $639,000.

Several other large investors have also recently made changes to their positions in HRMY. Barclays PLC grew its stake in shares of Harmony Biosciences by 110.9% during the 3rd quarter. Barclays PLC now owns 76,862 shares of the company's stock worth $3,074,000 after purchasing an additional 40,416 shares during the period. Franklin Resources Inc. boosted its stake in Harmony Biosciences by 6.1% during the third quarter. Franklin Resources Inc. now owns 29,773 shares of the company's stock worth $1,191,000 after buying an additional 1,720 shares during the period. JPMorgan Chase & Co. lifted its holdings in Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock worth $9,217,000 after buying an additional 93,622 shares in the last quarter. GAMMA Investing LLC increased its holdings in Harmony Biosciences by 92.6% during the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock worth $31,000 after purchasing an additional 436 shares during the period. Finally, CWA Asset Management Group LLC raised its holdings in Harmony Biosciences by 27.0% in the fourth quarter. CWA Asset Management Group LLC now owns 18,279 shares of the company's stock valued at $629,000 after acquiring an additional 3,883 shares in the last quarter. 86.23% of the stock is owned by institutional investors.

Harmony Biosciences Price Performance

Shares of HRMY traded up $0.46 during midday trading on Friday, hitting $30.32. 857,912 shares of the company traded hands, compared to its average volume of 574,832. The firm has a 50 day moving average of $31.54 and a 200-day moving average of $34.12. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock has a market cap of $1.74 billion, a price-to-earnings ratio of 14.37, a PEG ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 52 week low of $26.47 and a 52 week high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $201.30 million for the quarter, compared to analyst estimates of $201.25 million. During the same quarter in the prior year, the business posted $0.45 EPS. Harmony Biosciences's revenue for the quarter was up 19.5% compared to the same quarter last year. On average, analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HRMY. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. UBS Group dropped their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and set a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Deutsche Bank Aktiengesellschaft began coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective for the company. Finally, Mizuho increased their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 18th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harmony Biosciences currently has an average rating of "Buy" and an average target price of $52.44.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.